CL2008003194A1 -
Nitrogenous tricyclic compounds, histamine receptor modulators; pharmaceutical composition; pharmaceutical kit; and use of said compounds in the treatment of disorders such as cognitive, psychotic or neurological disorders.
- Google Patents
Nitrogenous tricyclic compounds, histamine receptor modulators; pharmaceutical composition; pharmaceutical kit; and use of said compounds in the treatment of disorders such as cognitive, psychotic or neurological disorders.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=68342365&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003194(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Neurology IncfiledCriticalMedivation Neurology Inc
Publication of CL2008003194A1publicationCriticalpatent/CL2008003194A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
Compuestos tricíclicos nitrogenados, moduladores del receptor de histamina; composición farmacéutica; kit farmacéutico; y uso en el tratamiento de trastornos tales como trastornos cognitivos, psicóticos o neurológicos.Nitrogenous tricyclic compounds, histamine receptor modulators; pharmaceutical composition; pharmaceutical kit; and use in the treatment of disorders such as cognitive, psychotic or neurological disorders.
CL2008003194A2007-10-252008-10-27
Nitrogenous tricyclic compounds, histamine receptor modulators; pharmaceutical composition; pharmaceutical kit; and use of said compounds in the treatment of disorders such as cognitive, psychotic or neurological disorders.
CL2008003194A1
(en)
Nitrogenous tricyclic compounds, histamine receptor modulators; pharmaceutical composition; pharmaceutical kit; and use of said compounds in the treatment of disorders such as cognitive, psychotic or neurological disorders.
Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
Compounds derived from imidazo [1,2-a] pyrazine; pharmaceutical composition; and use of the compounds as protein kinase inhibitors in the treatment of cancer.
Compounds derived from 3,8-diazabicyclo [2.4.0] octane and 3,6-diazabicyclo [3.2.0] heptane disubstituted, orexin receptor modulators; pharmaceutical composition; Useful in the treatment of sleep disorders, metabolic disorders, among others.
ARIL-SUBSTITUTED HETEROCICLIC COMPOUNDS, TYPE I CANNABINOID RECEIVER MODULATORS (CB1); PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS METABOLIC DISORDERS AND COGNITIVE DISORDERS.
Compounds derived from pyrazolo pyrimidines, inhibitors of pde9; pharmaceutical composition comprising said compounds; Useful in the treatment of a neurodegenerative and cognitive disorder such as Alzheimer's disease and schizophrenia.
Compounds derived from 3,8-diazabicyclo [4.2.0] octane and 3,6-diazabicyclo [3.2.0] heptane; pharmaceutical composition; orexin reeptor modulators, useful in the treatment of insomnia.
Compounds derived from 2,3,4,5-tetrahydro-1h-pyrido [4,3-b] indole; pharmaceutical composition comprising them; use in the treatment of neurodegenerative, cognitive or psychotic disorders, Alzheimer's disease, among others; and a kit containing the compounds.
Compounds derived from phenylaminopyrimidines, anaplastic lymphoma kinase inhibitors; pharmaceutical composition; pharmacological combination; and its use in the treatment of proliferative disorders such as lymphoma, osteosarcoma, melanoma or breast, renal and prostate tumor, among others (divisional application 3552-07).
Compounds derived from heterocycles, gamma secretase modulators; pharmaceutical composition; pharmaceutical kit; and use in the treatment of Alzheimer's.
Compounds derived from thiazolidinediones and substituted oxazolidinediones; pharmaceutical composition; process of preparation of the pharmaceutical composition; and use in the treatment of diseases such as rheumatoid arthritis, epoc, cancer, among others.
Compounds derived from 2-trifluoromethyl-1h-indole-5-methylcarboxamide, modulators of the alpha7 nicotinic acetylcholine receptor (nachr); pharmaceutical composition; and use for the treatment of cognitive impairment and a psychotic disorder such as schizophrenia.
Compounds derived from imidazo [1,2-a] pyridine; preparation procedure; pharmaceutical composition; intermediate compounds; and use in the treatment of cancer.
Substituted benzoazepine derived compounds; intermediate compounds; synthesis method; pharmaceutical composition; and use in the treatment or prevention of a central nervous system disorder.
Compounds derived from pyrazolopyridine; Preparation process; Pharmaceutical composition and use in the treatment of diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, among others.
COMPOUNDS DERIVED FROM PIRAZIN-2-ONA; PHARMACEUTICAL COMBINATION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DIABETES, ATEROSCLEROSIS, HYPERTENSION, AMONG OTHERS.
Compounds derived from substituted 2-heteroaryl-6-phenyl-imidazol [1,2-a] pyridines; not receptor modulators; intermediate compounds; preparation procedure; pharmaceutical composition; and use in the treatment of cancer, inflammation, neurodegenerative and psychiatric diseases, epilepsy, among others.
Compounds derived from 1,3-disubstituted-4-phenyl-1h-pyridin-2-one, allosteric modulators of the glutamatergic receptor mglur2; Pharmaceutical composition and use of the compounds in the treatment of neurological and psychiatric conditions mediated by mglur2.
Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer.
Compounds derived from furo and thienopyrimidine; pharmaceutical composition; method of modulating histamine h4 receptor activity; and use in the treatment of disorders such as inflammation, allergic and dermatological disorders, among others.